{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:51:18Z","timestamp":1789480278767,"version":"build-2803163510"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Leiomyosarcoma (LMS) is an aggressive malignancy characterized by a high risk of recurrence and metastasis. The prognosis for advanced LMS remains poor due to limited effective treatment options. We report a case of advanced bladder LMS in a male patient whose disease progressed following standard therapies including surgery, first-line chemotherapy, and anlotinib. Disease stabilization was achieved after two cycles of eribulin combined with sintilimab. Subsequently, a partial response was achieved after the addition of high-intensity focused ultrasound (HIFU) to this regimen, and the response was maintained for 7.2 months with continued eribulin and sintilimab. This sustained disease control suggests that the integration of HIFU may augment the antitumor activity of systemic therapy in advanced LMS, warranting further investigation into this multimodal approach for patients refractory to conventional treatments.<\/jats:p>","DOI":"10.3389\/fonc.2026.1775289","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:23:11Z","timestamp":1783570991000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Promising effects of high-intensity focused ultrasound combined with eribulin and sintilimab in a patient with advanced leiomyosarcoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Shaoli","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, the Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Cancer Center, Zhejiang University","place":["Hangzhou, China"]},{"name":"Department of Clinical Oncology, Li Ka Shing (LKS) Faculty of Medicine, the University of Hong Kong","place":["Hong Kong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglei","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Centre, The First Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, the Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Cancer Center, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, the Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Cancer Center, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, the Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Cancer Center, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, the Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Cancer Center, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11864-021-00897-2","article-title":"Leiomyosarcoma: does location of primary help to determine the best systemic therapy options","volume":"22","author":"Novotny","year":"2021","journal-title":"Curr Treat Opt. In. Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.00814.x","article-title":"Leiomyosarcomas of the oral cavity: an unusual topographic subset easily mistaken for nonmesenchymal tumours","volume":"36","author":"Dry","year":"2000","journal-title":"Histopathology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1149106","article-title":"Therapeutic advances in leiomyosarcoma","volume":"13","author":"Lacuna","year":"2023","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-47583-9_10","article-title":"Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","volume":"126","author":"D'Ambrosio","year":"2020","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10094","DOI":"10.1200\/jco.2011.29.15_suppl.10094","article-title":"Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS)","volume":"29","author":"Bitz","year":"2011","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100209","article-title":"A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery","volume":"6","author":"Pautier","year":"2021","journal-title":"ESMO. Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70070-7","article-title":"Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial","volume":"16","author":"Pautier","year":"2015","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00380-1","article-title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial","volume":"23","author":"Pautier","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22609","article-title":"Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial","volume":"109","author":"Dileo","year":"2007","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2016.1174582","article-title":"The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma","volume":"16","author":"Saponara","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.06.018","article-title":"Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: subgroup analysis of a phase 3, randomized clinical trial","volume":"146","author":"Hensley","year":"2017","journal-title":"Gynecol. Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1200\/jco.2016.34.15_suppl.11061","article-title":"Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS)","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet (Lond. Engl.)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Van Der Graaf","year":"2012","journal-title":"Lancet (Lond. Engl.)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","article-title":"Pazopanib in advanced soft tissue sarcomas","volume":"4","author":"Lee","year":"2019","journal-title":"Signal Transduc. Target. Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1686979","article-title":"The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib","volume":"19","author":"Wilding","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30726","article-title":"T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11512","DOI":"10.1200\/jco.2021.39.15_suppl.11512","article-title":"Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma","volume":"39","author":"Lagos","year":"2021","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11573","DOI":"10.1200\/jco.2022.40.16_suppl.11573","article-title":"Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161)","volume":"40","author":"Gordon","year":"2022","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1225","DOI":"10.1016\/j.annonc.2022.07.1586","article-title":"1483O Results of a phase I\/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma","volume":"33","author":"Gordon","year":"2022","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.1200\/jco.2023.41.16_suppl.11502","article-title":"ImmunoSarc2: a Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma","volume":"41","author":"Martin Broto","year":"2023","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11507","DOI":"10.1200\/jco.2023.41.16_suppl.11507","article-title":"Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)","volume":"41","author":"Cote","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1200\/jco.2023.41.16_suppl.11505","article-title":"A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas","volume":"41","author":"Agulnik","year":"2023","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11508","DOI":"10.1200\/jco.2023.41.16_suppl.11508","article-title":"Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: results from the low-dose expansion cohort","volume":"41","author":"Movva","year":"2023","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-021-02833-9","article-title":"High-intensity focused ultrasound: a review of mechanisms and clinical applications","volume":"49","author":"Bachu","year":"2021","journal-title":"Ann BioMed Eng"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2020.1807617","article-title":"Long-term follow-up outcome and reintervention analysis of ultrasound-guided high intensity focused ultrasound treatment for uterine fibroids","volume":"37","author":"Li","year":"2020","journal-title":"Int J Hyperthermia. Off J Eur Soc For. Hyperthermic. Oncol. North Am Hyperthermia. Group."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s40349-017-0097-8","article-title":"Ablative techniques for the treatment of benign and Malignant breast tumours","volume":"5","author":"Peek","year":"2017","journal-title":"J Ther Ultrasound."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601411","article-title":"A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer","volume":"89","author":"Wu","year":"2003","journal-title":"Br J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/his.12926","article-title":"Histopathology of breast cancer after magnetic resonance-guided high-intensity focused ultrasound and radiofrequency ablation","volume":"69","author":"Knutel","year":"2016","journal-title":"Histopathology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2021.0091","article-title":"Available evidence on HIFU for focal treatment of prostate cancer: a systematic review","volume":"48","author":"Bakavicius","year":"2022","journal-title":"Int Braz J Urol. Off J Braz Soc Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2019.06.004","article-title":"Significance of HIFU in local unresectable recurrence of soft tissue sarcoma, a single-center, respective, case series in China","volume":"30","author":"Yu","year":"2019","journal-title":"Surg Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07682-z","article-title":"Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers","volume":"31","author":"Marinova","year":"2021","journal-title":"Eur Radio."},{"key":"B41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/02656736.2021.1933217","article-title":"High-intensity focused ultrasound ablation of liver tumors in difficult locations","volume":"38","author":"Tsang","year":"2021","journal-title":"Int J Hyperthermia. Off J Eur Soc For. Hyperthermic. Oncol. North Am Hyperthermia. Group."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2021.1889698","article-title":"High-intensity focused ultrasound ablation in the treatment of recurrent ovary cancer and metastatic pelvic tumors: a feasibility study","volume":"38","author":"Lei","year":"2021","journal-title":"Int J Hyperthermia. Off J Eur Soc For. Hyperthermic. Oncol. North Am Hyperthermia. Group."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b00216","article-title":"Ablative focused ultrasound synergistically enhances thermally triggered chemotherapy for prostate cancer in vitro","volume":"13","author":"Arora","year":"2016","journal-title":"Mol Pharmaceutics."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2024.2430333","article-title":"Mechanical HIFU and immune checkpoint inhibition: toward clinical implementation","volume":"41","author":"Mekers","year":"2024","journal-title":"Int J Hyperthermia."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2025.106977","article-title":"High-intensity focused ultrasound treatment of unresectable soft tissue sarcoma and desmoid tumours \u2014 a systematic review","volume":"80","author":"Chetan","year":"2025","journal-title":"Clin Radiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:23:11Z","timestamp":1783570991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1775289"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1775289","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1775289"}}